RT annotation
T1 Phonophoresis through Nonsteroidal Anti-Inflammatory Drugs for Knee Osteoarthritis Treatment: Systematic Review and Meta-Analysis
A1 Martín Vega, Francisco Javier
A1 Lucena Antón, David Manuel
A1 Galán Mercant, Alejandro
A1 Pérez Cabezas, Verónica
A1 Luque-Moreno, Carlos
A1 Viñolo Gil, María Jesús
A1 González Medina, Gloria
A2 Enfermería y Fisioterapia
K1 osteoarthritis
K1 phonophoresis
K1 inflammation
K1 ultrasound
AB Knee osteoarthritis (OA) is the most common joint disease. The administration of nonsteroidal anti-inflammatory drugs (NSAIDs) by phonophoresis is a therapeutic alternative to relieve pain in inflammatory pathologies. The main aim was to analyze the efficacy of the application of NSAIDs by phonophoresis in knee OA. A systematic review and meta-analysis of controlled clinical trials were performed between January and March 2021 in the following databases: Web of Science, Scopus, PubMed, Cinahl, SciELO, and PEDro. The PEDro scale was used to evaluate the level of evidence of the selected studies. The RevMan 5.4 statistical software was used to obtain the meta-analysis. Eight studies were included, of which five were included in the meta-analysis, involving 195 participants. The NSAIDs used through phonophoresis were ibuprofen, piroxicam, diclofenac sodium, diclofenac diethylammonium, ketoprofen, and methyl salicylate. The overall result for pain showed not-conclusive results, but a trend toward significance was found in favor of the phonophoresis group compared to the control group (standardized mean difference (SMD) = −0.92; 95% confidence interval: −1.87–0.02). Favorable results were obtained for physical function (SMD = −1.34; 95% CI: −2.00–0.68). Based on the selected studies, the application of NSAIDs by phonophoresis is effective in relieving the symptoms of knee OA. Future long-term studies are recommended.
PB MDPI
SN 2227-9059
YR 2022
FD 2022
LK http://hdl.handle.net/10498/31003
UL http://hdl.handle.net/10498/31003
LA eng
DS Repositorio Institucional de la Universidad de Cádiz
RD 21-sep-2026